ArticleCancers2020
STAT3 Inhibits CD103
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 22 citations in OpenAlex.
- Antigen presentation requirements for effective cDC1-based cancer immunotherapy.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Review
- Antigen presentation requirements for effective cDC1-based cancer immunotherapy.bioRxiv : the preprint server for biology · 2026Article
- Toll-like receptors: versatile players in tumor.Frontiers in immunology · 2026Review
- Dual roles of innate immune cells and cytokines in shaping the breast cancer microenvironment.Frontiers in immunology · 2025Review
- Live Akkermansia muciniphila boosts dendritic cell retinoic acid synthesis to modulate IL-22 activity and mitigate colitis in mice.Microbiome · 2024Article
- Microbiota-derived butyrate inhibits cDC development via HDAC inhibition, diminishing their ability to prime T cells.Mucosal immunology · 2024Article
- CD103Cancers · 2024Article
- Review
- TIM-3 increases the abundance of type-2 dendritic cells during Leishmania donovani infection by enhancing IL-10 production via STAT3.Cell death & disease · 2023Article
- Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration.The Journal of experimental medicine · 2023Article
- STAT3 Inhibits Autocrine IFN Signaling in Type I Conventional Dendritic Cells.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Regulation and function of Id2 in plasmacytoid dendritic cells.Molecular immunology · 2022Article
- STAT3 Contributes to Intracranial Aneurysm Formation and Rupture by Modulating Inflammatory Response.Cellular and molecular neurobiology · 2021Article
- Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression.Cell communication and signaling : CCS · 2021Review
- From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.Frontiers in immunology · 2021Review
- Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review.Frontiers in immunology · 2021Review
- Clinical Data on Immunotherapy in Breast Cancer.Breast care (Basel, Switzerland) · 2020Review
- JAK-STAT Signalling Pathway in Cancer.Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Conventional dendritic cells (cDCs) are a critical immune population, composed of multiple subsets, and responsible for controlling adaptive immunity and tolerance. Although migratory type 1 cDCs (CD103
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.